References
- Alberti, K.G., Zimmet, P., Shaw, J. (2005) The metabolic syndrome—a new worldwide definition. Lancet, 366, 1059-1062.
- Anonīms (2010). Latvijas veselības statistikas gadagrāmata par 2009. gadu [Yearbook of Latvian Health Statistics for 2009]. Rīga: VSMTVA (Veselības statistikas un medicīnas tehnologiju valsts agentūra), 2010 (in Latvian).
- Anonymous (2011). Procoralan SPC (Summary of Product Characteristics)
- http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000597/WC500043590.pdf
- Anonymous (2008). The BEAUTIFUL Study Group. The BEAUTIFUL study: Randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction—baseline characteristics of the study population. Cardiology, 110, 271-282.
- Balode, I., Jēgere, S., Mintāle, I., Narbute, I., Zakke, I., Latkovskis, G., Ērglis, A. (2010). Current state of angina treatment in the outpatient population and heart rate monitoring survey in Latvia (REALITY Latvia). Proc. Latv. Acad. Sci., Section B, 64(5/6), 194-201.
- Boden, W.E., O'Rouke, R., Teo, K.T., Hartigan, P.M., Maron, D.J., Kostuk, W.I., Knudston, M., Dada, M., Casperson, P., Harris, C.L., Chaitman, B.R., Shaw, L., Gosselin, G., Navaz, S., Title, L.M. Gau, G., Blaustein, A.S., Booth, D.C., Bates, E.R., Spertus, J.A., Berman, D.S., Mancini, J., Weintraub, W.S. for the COURAGE Trial Research Group. (2007). Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl. J. Med., 356. www.nejm.org. http://www.nejm.org
- Bohm, M., Swedberg, K., Komajda, M., Borer, J., Ford, I., Dubost-Brama, A., Lerebous, G., Tavazzi, L., on behalf of the SHIFT investigators (2010). Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet, 376, 886-894.
- Daly, C.A., Clemens, F., Lopez Sendon, J. L., Tavazzi, L., Boersma, E., Danchin, N., Delahaye, F., Gitt, A., Julian, D., Mulcahy, D., Ruzyllo, W., Thygesen, K., Verheugt, F., Fox K.M. (2005). The initial management of stable angina in Europe, from the Euro Heart Survey: A description of pharmacological management and revascularization strategies initiated with the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina. Eur. Heart J., 26, 1011-1022.
- Daly, C.A., De Stavola, B., Lopez-Sendon, J. L., Tavazzi, L, Boersma, E., Clemens, F., Danchin, N., Delahaye, F., Gitt, A., Julian, D., Mulcahy, D., Ruzyllo, W., Thygesen, K., Verheugt, F., Fox K.M. (2006). Predicting prognosis in stable angina—results from the Euro Heart Survey of stable angina: Prospective observational study. BMJ, 332, 262-267.
- Daly, C., Tavazzi, L., Fox, K., Euro Heart Survey of Angina Investigators (2008) Inadequate control of heart rate in patients with stable angina: Results from the European Heart Survey. Eur. Heart J., 29 (Abstract Supplement), 204.
- Diaz, A., Bourassa, M. G., Guertin, M. C., Tardif, J. C. (2005). Long term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart J., 26(10), 967-974.
- Ērglis, A., Kalvelis, A., Lejnieks, A., Dzērve, V., Latkovskis, G., Mintāle, I., Zakke, I., Rasa, I. (2007). Kardiovaskulāro slimību (KVS) profilakses vadlīnijas [Guidelines on cardiovascular disease prevention]. Rīga. 45. lpp. (in Latvian).
- Fox, K., Garcia, M.A.A., Ardissino, D., Buszman, P., Camici, P.G., Crea, F., Daly, C., Backer, G., Hjemdahl, P., Lopes-Sendon, J., Marco, J., Morais, J., Pepper, J., Sechtem, U., Simoons, M., Thygesen, K. (2006). Guidelines on the management of stable angina pectoris. The Task Force on the Managment of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J., 27, 341-1381.
- Fox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., Ferrari, R., BEAUTIFUL investigators (2008a) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL):A subgroup analysis of a randomised controlled trial. Lancet, 372, 817-821.
- Fox, K., Ford, I., Steg, P. G., Tendera, M., Ferrari, R., BEAUTIFUL investigators (2008b) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet, 372, 807-816.
- Fox, K., Ford, I., Steg, P. G., Tendera, M., Robertson, M., Ferrari, R., BEAUTIFUL investigators (2009) Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic function with limiting angina: A subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart J., 30, 2337-2345.
- Gislason, G.H., Rasmussen, J.N., Abildstrom, S.Z., Gadsboll, N., Buch, P., Friberg, J., Rasmussen, S., Kober, L., Stender, S., Madsen, M., and Torp-Pederden, C. (2006). Long term compliance with beta-blockers, angiotensin-converting inhibitors, and statins after acute myocardial infarction. Eur. Heart J., 27, 1153-1158.
- Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., Gjelsvik, B., Herrmann-Lingen, C., Hoes, A., Humphries, S., Knapton, M., Perk, J., Priori, S.G., Pyorala, K., Reiner, Z., Ruilope, L., Sans-Menendez, S., Reimer, V.S.O., Weissberg, P., Wood, D., Yarnell, Y., Zamorano, J. L. (2007). European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Eur. Heart J., 28, 2375-2414.
- Leal, J., Luengo-Fernindez, R., Gray, A., Petersen, S., Rayner, M. (2006). Economic burden of cardiovascular diseases in the enlarged European Union. Eur. Heart J., 27(13), 1610-1619.
- Lopez-Sendon, J., Swedberg, K., McMurray J., Tamargo, J., Maggioni, A.P., Dargie, H.,Tendera, M., Waagstein, F., Kjekshus, J., Lechat, P., Torp-Pedersen, C. (2004). Expert consensus document on ā-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Eur. Heart J., 25, 1341-1362.
- Mathers, C.D., Loncar, D. (2006). Projections of global mortality and buren of disease from 2002 to 2030. PLoS Med., Nov, 3, e442.
- Tunstall-Pedoe, H., Kuulasmaa, K., Mahonen, M., Tolonen, H., Ruokokoski, E., Amouyel, P., for the WHO MONICA (monitoring trends and determinants in cardiovascular disease) Project (1999) Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet, 353, 1547-1557.
- Swedberg, K., Komajda, M., Bohm, M., Borer, J., Ford, I., Dubost-Brama, A., Lerebous, G., Tavazzi, L., on behalf of the SHIFT investigators (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet, 376, 875-885.